Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

被引:54
作者
Lefort, A
Pavie, J
Garry, L
Chau, F
Fantin, B
机构
[1] Univ Paris 07, F-75018 Paris, France
[2] Univ Paris 07, F-75018 Paris, France
关键词
D O I
10.1128/AAC.48.3.1061-1064.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.
引用
收藏
页码:1061 / 1064
页数:4
相关论文
共 9 条
[1]   In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic [J].
Candiani, G ;
Abbondi, M ;
Borgonovi, M ;
Romanò, G ;
Parenti, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :179-192
[2]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR MORB MORTAL WKL, V46, P765
[3]   Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].
Hiramatsu, K ;
Hanaki, H ;
Ino, T ;
Yabuta, K ;
Oguri, T ;
Tenover, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136
[4]   In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent [J].
Jones, RN ;
Biedenbach, DJ ;
Johnson, DM ;
Pfaller, MA .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (03) :244-254
[5]  
*NAT COMM CLIN LAB, 2001, M7A5 NAT COMM CLIN L
[6]   Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis [J].
Pavie, J ;
Lefort, A ;
Ploy, MC ;
Massias, L ;
Chau, F ;
Garry, L ;
Denis, F ;
Fantin, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :2018-2021
[7]   METHOD FOR RELIABLE DETERMINATION OF MINIMAL LETHAL ANTIBIOTIC CONCENTRATIONS [J].
PEARSON, RD ;
STEIGBIGEL, RT ;
DAVIS, HT ;
CHAPMAN, SW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (05) :699-708
[8]   First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [J].
Ploy, MC ;
Grélaud, C ;
Martin, C ;
de Lumley, L ;
Denis, F .
LANCET, 1998, 351 (9110) :1212-1212
[9]   Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis [J].
Saleh-Mghir, A ;
Lefort, A ;
Petegnief, Y ;
Dautrey, S ;
Vallois, JM ;
Le Guludec, D ;
Carbon, C ;
Fantin, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :115-120